Mr Krishna Prasad, managing director, Granules India
"The acquisition of Auctus fits into our strategy of being a fully integrated manufacturer while diversifying our product portfolio by adding high-value products with significant market demand. We will be a market leader by implementing our operational excellence philosophy while leveraging Auctus' regulatory approvals. In order to accelerate growth with a sustainable development engine, we have established a new R&D facility to enable finished dosage filings for our new APIs," said Mr Krishna Prasad, managing director, Granules India.
Currently, Auctus has two manufacturing facilities, an API facility in Vishakhapatnam and an intermediate facility in Hyderabad.
The API facility has approvals from regulatory agencies including the US FDA, EDQM and KFDA.
Auctus' APIs therapeutic categories includes Antihistaminic, Antihypertensive, Antithrombotic and Anticonvulsant.
Granules also announced the opening of its 10,000 sq. foot R&D facility in Hyderabad.